Advanced materials have become pivotal in the transformation of healthcare. They are not merely functional components, they symbolize a significant leap in our ability to diagnose, treat, and manage diseases. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Venture Capital Funding Flowing into the iPSC Sector by Year
The induced pluripotent stem cell (iPSC) sector has attracted strong venture capital funding in recent years, reflecting growing confidence in its potential across regenerative medicine, drug development, toxicology testing, personalized medicine, and disease modeling. From 2021 to 2024, numerous companies secured substantial investments, signaling a promising future for iPSC-based innovations.
This article examines key funding events in the sector, analyzing the scale of investments, their trajectory over time, and the companies driving industry growth. [Read more…]
Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time
The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.
PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]
Cord Blood Banking in Latin America – Interview with James Mendez of Cryoholdco
In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco. Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. [Read more…]
Amniotic Stem Cells: An Extension of the Cord Blood Banking Model
Amniotic stem cells, which can be sourced from the amniotic fluid or the placenta after a live, healthy birth, possess a unique blend of multipotency and lack of tumorigenicity. In an extension of the cord blood banking model, these cells may improve outcomes where long-term cell survival and functionality is important. Recently, I had the honor of interview Dr. Todd McAllister, Executive Director at the Amnion Foundation, a non-profit organization with the mission to build a genetically diverse public cell bank that can provide an immunological match to the majority of the population.
In this interview, we discuss the Amnion Foundation’s vision, research and clinical approach, scale-out strategy, and interest in joint partnerships that will support greater utilization of amniotic stem cells. It is captivating to get an insider look at the Amnion Foundation, a non-profit that is introducing a new extension to the traditional cord blood and tissue banking market.
As the cord blood banking market matures and consolidates and diversifies into new types of perinatal stem cell storage, the Amnion Foundation will be uniquely positioned to advise cord blood banks on how to integrate amniotic stem cell banking into their service portfolio.
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 62
- Next Page »